Ocugen Shares Jump 20%

Shares of Ocugen, Inc. (OCGN) gained nearly 20% on Monday despite no-stock related news to drive the shares.

OCGN is currently trading at $8.56, up $1.41 or 19.72%, on the Nasdaq, on a volume of 54 million shares, far above average volume of 18 million shares. The stock has traded between $0.25 and $18.77 in the 52-week period. The stock has surged over 360% in that period.

Ocugen, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT